Correlation Between GlaxoSmithKline PLC and Ubs Emerging
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and Ubs Emerging at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and Ubs Emerging into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and Ubs Emerging Markets, you can compare the effects of market volatilities on GlaxoSmithKline PLC and Ubs Emerging and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of Ubs Emerging. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and Ubs Emerging.
Diversification Opportunities for GlaxoSmithKline PLC and Ubs Emerging
-0.35 | Correlation Coefficient |
Very good diversification
The 3 months correlation between GlaxoSmithKline and Ubs is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and Ubs Emerging Markets in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ubs Emerging Markets and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with Ubs Emerging. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ubs Emerging Markets has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and Ubs Emerging go up and down completely randomly.
Pair Corralation between GlaxoSmithKline PLC and Ubs Emerging
Considering the 90-day investment horizon GlaxoSmithKline PLC is expected to generate 1.71 times less return on investment than Ubs Emerging. In addition to that, GlaxoSmithKline PLC is 1.29 times more volatile than Ubs Emerging Markets. It trades about 0.01 of its total potential returns per unit of risk. Ubs Emerging Markets is currently generating about 0.02 per unit of volatility. If you would invest 705.00 in Ubs Emerging Markets on August 30, 2024 and sell it today you would earn a total of 72.00 from holding Ubs Emerging Markets or generate 10.21% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
GlaxoSmithKline PLC ADR vs. Ubs Emerging Markets
Performance |
| Timeline |
| GlaxoSmithKline PLC ADR |
| Ubs Emerging Markets |
GlaxoSmithKline PLC and Ubs Emerging Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with GlaxoSmithKline PLC and Ubs Emerging
The main advantage of trading using opposite GlaxoSmithKline PLC and Ubs Emerging positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, Ubs Emerging can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ubs Emerging will offset losses from the drop in Ubs Emerging's long position.| GlaxoSmithKline PLC vs. Novartis AG ADR | GlaxoSmithKline PLC vs. AstraZeneca PLC ADR | GlaxoSmithKline PLC vs. Roche Holding Ltd | GlaxoSmithKline PLC vs. Bristol Myers Squibb |
| Ubs Emerging vs. Goldman Sachs Mlp | Ubs Emerging vs. Oil Gas Ultrasector | Ubs Emerging vs. Energy Services Fund | Ubs Emerging vs. Hennessy Bp Energy |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |